New OptiPact™ Technology Introduced By Catalent

Somerset, N.J.— Catalent Pharma Solutions, the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, has announced the launch of OptiPact™, an integrated service and technology offer based on the company's expertise in roller compaction, and provided from the company's 450,000 sq. ft. Kansas City, MO facility.

OptiPact technology describes Catalent's ability to integrate optimal formulation, development, analytical expertise, scale up and manufacturing capabilities to create differentiated final dosage forms.

Roller compaction provides the optimum granulation technology for materials that are sensitive to heat and moisture. Unlike wet granulation processes, OptiPact does not require liquid binders, alcohol solvents and high temperature drying, resulting in a more consistent, higher quality granule, often at a lower cost, and avoiding the instability risks inherent with moisture.

"Catalent has over twenty years' experience in roller compaction technology and employs multiple roller compactors capable of supplying pilot feasibility programs to cGMP development and commercial scale," commented Matthew Mollan, Catalent's General Manager, Development and Analytical Solutions. "This expertise has helped Catalent's partners to fast track two products to market over the past eighteen months, and we currently have multiple further products in all phases of clinical development."

Catalent's facility in Kansas City provides a range of fully integrated support services, from formulation development and analytical testing, to clinical and commercial scale manufacturing and packaging of a variety of oral dose forms. Its co-located end-to-end drug development solutions provide speed and flexibility to help Catalent's customers accelerate their drug development programs to market.

Media Contacts:
Chris Halling
+44 (0)7580 041073
[email protected]

Richard Kerns
+44 (0) 161 728 5880
[email protected] 


Catalent Pharma Solutions is the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products. With over 80 years serving the industry, Catalent has proven expertise in bringing more customer products to market faster, enhancing product performance and ensuring reliable clinical and commercial product supply. Catalent employs approximately 8,000 people, including over 1,000 scientists, at 27 facilities across 5 continents, and in fiscal 2014 generated more than $1.8 billion in annual revenue. Catalent is headquartered in Somerset, N.J. For more information, visit

Suggested Articles

Dubbed “Project Nightingale,” the efforts were announced amid concerns and federal inquiries into the data’s safekeeping and patient consent for use.

Independent site management organization Panthera Biopartners has kick-started its first clinical trial in the U.K.

WIRB-Copernicus Group’s clinical services division bought out trial consultancy firm Waife & Associates as it looks to boost its management services.